In a further aspect, there is provided use of a polypeptide as defined above for the manufacture of a medicament for the treatment, prevention or alleviation of a disease, disorder or condition, in a human being.

In a further aspect, there is provided use of polypeptide as defined above in the manufacture of a medicament for the treatment or prevention of CX3CR1-associated disease or disorder.

In a further aspect, there is provided a diagnostic kit ~~or diagnostic method~~ comprising a polypeptide as defined above, or the use thereof

In a further aspect, there is provided a polypeptide comprising the amino acid sequence of SEQ ID NO: 225.

In a further aspect, there is provided a polypeptide comprising the amino acid sequence of SEQ ID NO: 226.

In a further aspect, there is provided a polypeptide comprising the amino acid sequence of SEQ ID NO: 227.

In a further aspect, there is provided a polypeptide comprising the amino acid sequence of SEQ ID NO: 258.

In a further aspect, there is provided a polypeptide comprising the amino acid sequence of SEQ ID NO: 261.

In a further aspect, there is provided a pharmaceutical composition comprising (i) a polypeptide as defined above, and (ii) a pharmaceutically acceptable carrier, and optionally (iii) a diluent, excipient, adjuvant and/or stabilizer.

The polypeptides of the present disclosure are used for the prevention, treatment, alleviation and/or diagnosis of CX3CR1-associated diseases, disorders or conditions, in particular cardiovascular diseases, such as atherosclerosis.

The present disclosure may provide:

Embodiment 1: An immunoglobulin comprising an antigen-binding domain comprising three complementarity determining regions CDR1, CDR2 and CDR3, wherein said immunoglobulin binds to human CX3CR1 and is capable of blocking the binding of human fractalkine to human CX3CR1.

32. A diagnostic kit ~~or diagnostic method~~ comprising a polypeptide according to any one of claims 1 to 16, or the use thereof.

33. A diagnostic kit ~~or diagnostic method~~ according to claim 32, for the diagnosis of at least one of cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, restenosis, diabetic nephropathy, glomerulomephritis, human crescentic glomerulonephritis, IgA nephropathy, membranous nephropathy, lupus nephritis, vasculitis including Henoch-Schonlein purpura and Wegener's granulomatosis, rheumatoid arthritis, osteoarthritis, allograft rejection, systemic sclerosis, neurodegenerative disorders and demyelinating disease, multiple sclerosis (MS), Alzheimer's disease, pulmonary diseases such as COPD, asthma,neuropathic pain, inflammatory pain, or cancer.

34. A polypeptide comprising the amino acid sequence of SEQ ID NO: 225.

35. A polypeptide comprising the amino acid sequence of SEQ ID NO: 226.

36. A polypeptide comprising the amino acid sequence of SEQ ID NO: 227.

37. A polypeptide comprising the amino acid sequence of SEQ ID NO: 258.

38. A polypeptide comprising the amino acid sequence of SEQ ID NO: 261.

39. A pharmaceutical composition comprising (i) a polypeptide according to claim 35, and (ii) a pharmaceutically acceptable carrier, and optionally (iii) a diluent, excipient, adjuvant and/or stabilizer.

40. A pharmaceutical composition comprising (i) a polypeptide according to claim 36, and (ii) a pharmaceutically acceptable carrier, and optionally (iii) a diluent, excipient, adjuvant and/or stabilizer.

41. A pharmaceutical composition comprising (i) a polypeptide according to claim 37, and (ii) a pharmaceutically acceptable carrier, and optionally (iii) a diluent, excipient, adjuvant and/or stabilizer.